Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382549 · ClinicalTrials.gov registry record · Early Phase 1
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
A Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02382549 is a Early Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 8 participants.
The verdict
NCT02382549, a Early Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by performing tests in the laboratory on participants' blood and tumor samples.
Interventions
- BIOLOGICAL 6MHP
- DRUG BRAF inhibitor
- DRUG MEK inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02382549
The ClinicalTrials.gov registry entry for NCT02382549 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 6MHP is the first listed.
NCT02382549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02382549 about?
NCT02382549 is a clinical study titled "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib". This study evaluates whether it is safe to administer a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy. This study will also evaluate the effects of the combination of the peptide vaccine and BRAF inhibitors/MEK inhibitors on the immune system. We will monitor these effects by ...
What is the current status of trial NCT02382549?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2016-04. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT02382549?
The interventions under investigation include: 6MHP (BIOLOGICAL), BRAF inhibitor (DRUG), MEK inhibitor (DRUG).
Who is sponsoring clinical trial NCT02382549?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.